Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Akebia Therapeutics (AKBA) Current Leases (2019 - 2020)

Akebia Therapeutics has reported Current Leases over the past 2 years, most recently at $5.1 million for Q1 2020.

Quarterly Current Leases fell 83.72% to $5.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Mar 2020, down 83.72% year-over-year, with the annual reading at $5.0 million for FY2019, N/A changed from the prior year.
Current Leases was $5.1 million for Q1 2020 at Akebia Therapeutics, up from $5.0 million in the prior quarter.
Over five years, Current Leases peaked at $31.3 million in Q1 2019 and troughed at $4.8 million in Q2 2019.